Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature

Heath, 2020, The biology and rationale of targeting nectin-4 in urothelial carcinoma, Nat Rev Urol, 18, 93, 10.1038/s41585-020-00394-5 Challita-Eid, 2016, Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models, Cancer Res, 76, 3003, 10.1158/0008-5472.CAN-15-1313 Powles, 2021, Enfortumab vedotin in previously treated advanced urothelial carcinoma, N Engl J Med, 384, 1125, 10.1056/NEJMoa2035807 Yu, 2021, Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV–201): a multicentre, single-arm, phase 2 trial, Lancet Oncol, 22, 872, 10.1016/S1470-2045(21)00094-2 Rosenberg, 2019, Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy, J Clin Oncol, 37, 2592, 10.1200/JCO.19.01140 Rosenberg, 2020, EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma, J Clin Oncol, 38, 1041, 10.1200/JCO.19.02044 Takahashi, 2020, A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma, Invest New Drugs, 38, 1056, 10.1007/s10637-019-00844-x Younes, 2010, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, N Engl J Med, 363, 1812, 10.1056/NEJMoa1002965 Lacouture, 2022, Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin implications for practice, Oncologist, 27, 223, 10.1093/oncolo/oyac001 Oh, 2021, Dermatologic adverse events of brentuximab vedotin: characteristics, management, and their relationship with dose regimen, J Clin Oncol, 39, 3049, 10.1200/JCO.2021.39.15_suppl.3049